fulvestrant has been researched along with Lung Adenocarcinoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Gaofeng, P; Hexiao, T; Jinping, Z; Lanuti, M; Lecai, X; Li, S; Li, Z; Ming, X; Minglin, Z; Weidong, H; Xiao, Z; Xuefeng, Z; Yanhong, W; Yi, C; Yuquan, B; Zetian, Y; Zheng, T | 1 |
1 other study(ies) available for fulvestrant and Lung Adenocarcinoma
Article | Year |
---|---|
Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERĪ²2/5 pathway.
Topics: Adenocarcinoma of Lung; Animals; Chromosomal Proteins, Non-Histone; Computational Biology; Databases, Factual; Disease Progression; Estrogen Receptor Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Microfilament Proteins; Signal Transduction | 2021 |